India, April 1 -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Vancomycin Hydrochloride for Injection USP in 750 mg/vial, 1.25 g/vial, and 1.5 g/vial single-dose vials. The product is bioequivalent and therapeutically equivalent to the reference listed drug manufactured by Mylan Laboratories Limited (NDA 209481).
According to IQVIA™ sales data for the 12-month period ending January 2025, the market for Vancomycin Hydrochloride for Injection in these strengths achieved annual sales of approximately $39.3 million.
Expressing his enthusiasm about the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to introduce Vancomycin Hydrochloride for Injection, expanding our institu...